Pembrolizumab combined with chemotherapy for advanced and recurrent endometrial cancer: A single-center retrospective study
Pembrolizumab combined with chemotherapy may provide clinical benefits, particularly in patients with dMMR status, as the first-line treatment for endometrial cancer. Lower dosing may also be feasible in Asian populations, although further validation is warranted.
Authors
- Wen‐Chun Chang (ORCID: https://orcid.org/0000-0002-7519-7878)
- Kuang-Yen Lee (ORCID: https://orcid.org/0009-0003-8157-8073)
- Bor‐Ching Sheu (ORCID: https://orcid.org/0000-0003-1278-6082)
- Lin‐Hung Wei (ORCID: https://orcid.org/0000-0001-8789-0859)
- Annan Yang (ORCID: https://orcid.org/0000-0002-6750-0304)
- Ying‐Cheng Chiang (ORCID: https://orcid.org/0000-0002-8958-5222)
- Jiun-Yi Sheen
- Yu-Ting Lin
Institutions
- National Taiwan University Hospital (TW)
- National Yunlin University of Science and Technology (TW)
Publication Details
- Journal
- Journal of the Formosan Medical Association
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.jfma.2025.10.026
- Citations
- 3
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.17